Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen

Inclusion Criteria:

* Histologic or cytologic diagnosis of stage IIIB/IV NSCLC
* ECOG PS: 0,1
* Unidimensional or bi-dimensional measurable disease
* Receive prior treatment including first-line platinum-based chemotherapy, standard second-line chemotherapy and 1 EGF/EGFR inhibitor
* Evidence of disease progression
* Life expectancy \>12 weeks
* Neutrophils \> 1.5 109/l, Platelets \> 100 109/l, Hemoglobin \> 9g/dl, Total bilirubin \< 1.5 UNL, AST (SGOT) and ALT (SGPT) \< 2.5 UNL, Alkaline phosphatases \< 5 UNL, Creatinine \< 1 UNL

Exclusion Criteria:

* Pre-existing hemoptysis of a severity \> grade 3 by NCI CTCAE criteria within 4 weeks prior to study entry
* Uncontrolled hypertension
* CHF, angina or arrhythmias
* LVEF \< 1 UNL
* Existing a second malignancy within 5 years
* Infected with HIV